- Home
- OTLK vs BRFH Comparison
OTLK vs BRFH Comparison
Compare OTLK & BRFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- BRFH
- Stock Information
- Founded
- OTLK 2010
- BRFH 2005
- Country
- OTLK United States
- BRFH United States
- Employees
- OTLK N/A
- BRFH N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- BRFH Packaged Foods
- Sector
- OTLK Health Care
- BRFH Consumer Staples
- Exchange
- OTLK Nasdaq
- BRFH Nasdaq
- Market Cap
- OTLK 48.3M
- BRFH 43.8M
- IPO Year
- OTLK 2016
- BRFH N/A
- Fundamental
- Price
- OTLK $1.53
- BRFH $2.52
- Analyst Decision
- OTLK Strong Buy
- BRFH Strong Buy
- Analyst Count
- OTLK 5
- BRFH 1
- Target Price
- OTLK $10.20
- BRFH $4.50
- AVG Volume (30 Days)
- OTLK 274.9K
- BRFH 7.2K
- Earning Date
- OTLK 05-19-2025
- BRFH 05-01-2025
- Dividend Yield
- OTLK N/A
- BRFH N/A
- EPS Growth
- OTLK N/A
- BRFH N/A
- EPS
- OTLK N/A
- BRFH N/A
- Revenue
- OTLK N/A
- BRFH $10,818,000.00
- Revenue This Year
- OTLK N/A
- BRFH $41.20
- Revenue Next Year
- OTLK $288.46
- BRFH $42.03
- P/E Ratio
- OTLK N/A
- BRFH N/A
- Revenue Growth
- OTLK N/A
- BRFH 22.03
- 52 Week Low
- OTLK $0.87
- BRFH $1.44
- 52 Week High
- OTLK $9.25
- BRFH $4.61
- Technical
- Relative Strength Index (RSI)
- OTLK 55.94
- BRFH 44.35
- Support Level
- OTLK $1.35
- BRFH $2.30
- Resistance Level
- OTLK $1.62
- BRFH $2.69
- Average True Range (ATR)
- OTLK 0.10
- BRFH 0.17
- MACD
- OTLK -0.00
- BRFH 0.02
- Stochastic Oscillator
- OTLK 54.55
- BRFH 29.24
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About BRFH Barfresh Food Group Inc.
Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.